Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 22Gastrointestinal 8Head & Neck 5Gynecologic 3Breast 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Endocrine 1Dermatologic 1CNS 1

Conditions

Pheochromocytoma 1

Interventions

Observation 2Interviews as Topic 2Fluorouracil 2Carboplatin 2Adrenalectomy 2zimberelimab 1trametinib 1lutetium Lu 177 dotatate 1dabrafenib 1cemiplimab 1apatinib 1anlotinib 1Watchful Waiting 1Thyroxine 1Surveys and Questionnaires 1Standard of Care 1Radiomics 1Radiation 1Positron Emission Tomography Computed Tomography 1Mitoxantrone 1Leucovorin 1Irinotecan 1Injections 1IFL protocol 1Etoposide 1Engineering 1Endoscopic Mucosal Resection 1Decision Support Techniques 1Counseling 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × anlotinib × Endocrine × Clear all
NCT06429397 2025-04-29

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Sun Yat-sen University

Phase 2 Not yet recruiting
22 enrolled
Endocrine

Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡